Psychostimulants

Phase 2Small molecule

UUniversity of British Columbia

Psychostimulants is one of 11 small molecule programs targeting Executive Function. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Executive FunctionActive, not recruiting

Executive FunctionPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Executive Function

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

2 2

Adhansia Xr

Novartis

Approved

1 3

Azilect

Teva

Approved

1 4

Vyvanse

Takeda

Approved

1 5

Strattera

MMap77

Approved

1 6

Intuniv

PPromius Pharma, LLC

Approved

1 7

Tasmar

BBausch Health Americas, Inc.

Approved

—8

Kuvan

BioMarin Pharmaceutical

Preclinical

1 9

Reminyl

WWim Janssens

Preclinical

1 10

Nicotine Replacement

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Executive Function1 trial

Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD

Active, not recruiting·UUniversity of British Columbia·Phase 1/2·NCT02167048·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Psychostimulants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psychostimulants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psychostimulants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of British Columbia

Psychostimulants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Executive Function1 trial

References

Drug Info

Quick Facts

Related News